Alnylam Pharmaceuticals (BSP:A1LN34) Price-to-Tangible-Book : (As of May. 13, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-13), Alnylam Pharmaceuticals's share price is R$38.92. Alnylam Pharmaceuticals's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was R$-0.43. Hence, Alnylam Pharmaceuticals's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Alnylam Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Alnylam Pharmaceuticals's highest Price to Tangible Book Ratio was 100.24. The lowest was 3.50. And the median was 6.62.

BSP:A1LN34's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.71
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Alnylam Pharmaceuticals's share price is R$38.92. Alnylam Pharmaceuticals's Book Value per Sharefor the quarter that ended in Mar. 2024 was R$-0.43. Hence, Alnylam Pharmaceuticals's P/B Ratio of today is .

Alnylam Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Alnylam Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Price-to-Tangible-Book Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

14.23

33.98

Alnylam Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Alnylam Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Price-to-Tangible-Book falls into.

Alnylam Pharmaceuticals Price-to-Tangible-Book Calculation

Alnylam Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	38.92	/	-0.432
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Alnylam Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines